Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. (17th October 2021)

• Record Type: Journal Article
• Authors: Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; Yassine, Hadi M; Benslimane, Fatiha M; Al Khatib, Hebah A; Tang, Patrick; Hasan, Mohammad R; Coyle, Peter; AlMukdad, Sawsan; Al Kanaani, Zaina; Al Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul Rahim, Hanan F; Nasrallah, Gheyath K; Al Kuwari, Mohamed Ghaith; Butt, Adeel A; Al Romaihi, Hamad Eid; Al-Thani, Mohamed H; Al Khal, Abdullatif; Bertollini, Roberto
• Is Part Of: Clinical infectious diseases. Volume 75:Number 1(2022)
• Page Start: e1188
• Page End: e1191
• Publication Date: 2021-10-17
• Subjects: SARS-CoV-2 -- variant -- infection -- severe disease -- epidemiology; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab909
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Beta (B.1.351)–variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19–related death were 1.24-fold (1.11–1.39), 1.49-fold (1.13–1.97), and 1.57-fold (1.03–2.43) higher, respectively, for the Beta variant.